Chalmers I - Search Results

1

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.

Burgess CJ, Jackson R, Chalmers I, Russell RK, Hansen R, Scott G, Henderson P, Wilson DC. Burgess CJ, et al. Among authors: chalmers i. Aliment Pharmacol Ther. 2022 Nov;56(10):1453-1459. doi: 10.1111/apt.17217. Epub 2022 Oct 4. Aliment Pharmacol Ther. 2022. PMID: 36196524 Free PMC article.

2

Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful.

Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, Garrick V, Armstrong K, Tayler R, Henderson P, Hansen R, Chalmers I, Wilson DC, Russell RK. Gervais L, et al. Among authors: chalmers i. J Pediatr Gastroenterol Nutr. 2018 Dec;67(6):745-748. doi: 10.1097/MPG.0000000000002091. J Pediatr Gastroenterol Nutr. 2018. PMID: 29985877 Free article.

3

The Epidemiology of Pediatric Autoimmune Hepatitis in Scotland: A National Cohort Study.

Sutton H, Tayler R, Chalmers I, Cowieson J, Fraser K, Henderson P, Hansen R. Sutton H, et al. Among authors: chalmers i. JPGN Rep. 2022 Jul 29;3(3):e223. doi: 10.1097/PG9.0000000000000223. eCollection 2022 Aug. JPGN Rep. 2022. PMID: 37168624 Free PMC article.

4

Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn's Disease and Emerging Combination Strategy With Biologics.

Wands DIF, Gianolio L, Wilson DC, Hansen R, Chalmers I, Henderson P, Gerasimidis K, Russell RK. Wands DIF, et al. Among authors: chalmers i. Inflamm Bowel Dis. 2023 Aug 24:izad167. doi: 10.1093/ibd/izad167. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37619221

5

Protease concentration in amniotic fluid at term and early childhood respiratory symptoms.

Turner SW, Carter J, Danielian P, Chalmers I, McConaghy L, Pacitti N, Booth N. Turner SW, et al. Among authors: chalmers i. J Matern Fetal Neonatal Med. 2014 Mar;27(4):416-20. doi: 10.3109/14767058.2013.818647. Epub 2013 Jul 24. J Matern Fetal Neonatal Med. 2014. PMID: 23796141

6

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.

7

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.

8

The differences and overlaps between 'explanatory' and 'pragmatic' controlled trials: a historical perspective.

Glasziou P, Matthews R, Boutron I, Chalmers I, Armitage P. Glasziou P, et al. Among authors: chalmers i. J R Soc Med. 2023 Dec;116(12):425-432. doi: 10.1177/01410768231207536. Epub 2023 Nov 22. J R Soc Med. 2023. PMID: 37991449 No abstract available.

9

Trial analysis by treatment allocated or by treatment received? Origins of 'the intention-to-treat principle' to reduce allocation bias: Part 2.

Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Chalmers I, et al. J R Soc Med. 2023 Nov;116(11):386-394. doi: 10.1177/01410768231203936. Epub 2023 Nov 17. J R Soc Med. 2023. PMID: 37975723 No abstract available.

10

Trial analysis by treatment allocated or by treatment received? Origins of 'the intention-to-treat principle' to reduce allocation bias: Part 1.

Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Chalmers I, et al. J R Soc Med. 2023 Oct;116(10):343-350. doi: 10.1177/01410768231203922. J R Soc Med. 2023. PMID: 37961883 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

458 results

Search Page